Giacomo Giulio Baldi

Hospital of Prato

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Silvia Stacchiotti

Fondazione IRCCS Istituto Nazionale dei Tumori

Paolo G. Casali

Fondazione IRCCS Istituto Nazionale dei Tumori

Bruno Vincenzi

Università Campus Bio-Medico

Alessandro Gronchi

Fondazione IRCCS Istituto Nazionale dei Tumori

Alfredo Falcone

Azienda Ospedaliera Universitaria Pisana

Angelo Paolo Dei Tos

University of Padua

Fotios Loupakis

Istituto Oncologico Veneto

Gianluca Masi

Azienda Ospedaliera Universitaria Pisana

Anna Maria Frezza

Fondazione IRCCS Istituto Nazionale dei Tumori

Antonella Brunello

Istituto Oncologico Veneto

Cooperative Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

169

Fondazione IRCCS Istituto Nazionale dei Tumori

121

University of Pisa

Azienda Ospedaliera Universitaria Pisana

University of Florence

University of Milan

Media Working Group

Azienda Ospedaliero-Universitaria Careggi

University of Bologna

Istituto Ortopedico Rizzoli

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

6081 Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II G.O.N.O. trial

European Journal of Cancer Supplements (2009)

Gianluca Masi Lisa Salvatore Lorenzo Fornaro Enrico Vasile Giacomo Giulio Baldi

FOLFIRI

10.1016/s1359-6349(09)71176-0

Cite

Citations (3)

Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)

Current Cancer Drug Targets (2010)

Daniele Santini Gaia Schiavon Bruno Vincenzi Carol E. Cass Enrico Vasile

Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy.The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens.Positive hENT1 staining patients were 21 (67.7%); negative hENT1 staining patients were 10 (32.3%). Statistical analysis revealed no association between baseline characteristics, toxicities and tumor response to gemcitabine and hENT1 levels. In the univariate analysis, HENT1 expression was significantly correlated with time to progression (TTP) (p=0.0394; HR 2.902, 95%CI 1.053-7.996). The median TTP was 6.33 versus 2.83 months, respectively in patients with positive versus negative hENT1 staining. Moreover, patients with positive hENT1 expression showed a longer median overall survival when compared with patients with low hENT1 expression (14 versus 7 months, respectively), but this difference did not reach the statistical significance (p=0.128).Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in patients with advanced BTC.

Regimen

Univariate analysis

Nucleoside transporter

10.2174/156800911793743600

Cite

Citations (47)

Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional referral center experience in advanced disease.

Journal of Clinical Oncology (2019)

Roberta Sanfilippo Marta Sbaraglia Elena Fumagalli Giacomo Giulio Baldi Giovanni Fucà

11066 Background: STUMP ecompass a group of uterine mesenchymal neoplasms in which the clinical behavior cannot be predicted on morphological grounds. A malignant clinical evolution is seen in approximately 10-20% of cases. When STUMP relapse, the label of “low-grade leiomyosarcoma” is sometimes found to be appropriate, though current histopathological criteria for uterine leiomyosarcoma (so called “Stanford criteria”) would exclude even the existence of low-grade uterine smooth muscle neoplasms. As they express ER and PR, hormonal treatment with GnRH inhibitors or aromatase inhibitors (AIs) may represent a therapeutic option. Methods: From October 2015, we have been treating with hormonal therapy relapsing patients with an initial diagnosis of STUMP, whose pathological aspect on retrospect was consistent with a “low-grade uterine leiomyosarcoma”. We identified 8 patients. Pathological diagnosis was centrally reviewed by expert sarcoma pathologists. Results: Eight pts were treated: 7 in first line; 1 pt in 4th line, following failure of chemotherapy (gemcitabine and taxotere, adriamycin and dacarbazine, trabectedin). Two premenopauseal pts were treated with GnRH inhibitors, 2 with a combination of GnRh inhibitors and an aromatase inhibitor, 3 with aromatase inhibitors only and 1 with selective progesterone-receptor modulator. 7 patients are evaluable for response and all of them had a partial response as best response. Median progression-free survival was 31 months. Conclusions: In our series, all patients with a centrally reviewed diagnosis retrospectively consistent with a “low grade uterine leiomyosarcoma” responded to hormonal treatment. Therefore, these pts may make up a subgroup with therapeutic and prognostic relevance. “Stanford criteria” need to be re-assessed, in an effort to improve prognostic and therapeutic stratification of uterine smooth muscle neoplasms, possibly shrinking the scope of currently defined STUMP.

Hormonal Therapy

Dacarbazine

Uterine sarcoma

Trabectedin

Anastrozole

10.1200/jco.2019.37.15_suppl.11066

Cite

Citations (2)

TRATTAMENTO CHIRURGICO O CONSERVATIVO NELLA FIBROMATOSI AGGRESSIVA: LA NOSTRA ESPERIENZA

Scorianz Maurizio Cuomo Pierluigi Nicola Mondanelli Mazzei Giacomo Giacomo Giulio Baldi

Source

Cite

Citations (0)

3063 POSTER Capecitabine (C), in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)

European Journal of Cancer Supplements (2007)

S. Bursi Gianluca Masi Fotios Loupakis Andrea Antonuzzo S. Chiara

FOLFOX

FOLFIRI

10.1016/s1359-6349(07)70991-6

Cite

Citations (1)

Utilizzo di Denosumab nel tumore a cellule giganti dell'osso : innovazione o chimera?

Giovanni Beltrami Giacomo Giulio Baldi Guido Scoccianti Antonio D’Arienzo Francesco Rosario Campo

Chimera (genetics)

Denosumab

Source

Cite

Citations (0)

Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid‐type fibromatosis

Cancer Medicine (2021)

Edoardo Zanchetta Chiara Maura Ciniselli Annalisa Bardelli Chiara Colombo Silvia Stacchiotti

We aimed to investigate changes in volume and MRI T2-weighted intensity in desmoid-type fibromatosis (DF) receiving methotrexate plus vinca-alkaloids (MTX-VA) at Istituto Nazionale dei Tumori, Milan.All cases of sporadic DF treated with MTX-VA from 1999 to 2019 were reviewed. MRIs at baseline, 6 and 12 months of chemotherapy and at treatment withdrawal were retrospectively reviewed, contouring the tumor lesion and measuring diameters, volume, and mean T2-signal intensity (normalized to muscle) changes. These parameters were also evaluated according to clinical variables.Thirty-two DF patients were identified. Best RECIST response was: 25% partial response, 69% stable disease, 6% progression. A ≥65% tumor volume reduction was observed in 38%, <65% reduction in 53%, an increase in 9%. 22% had RECIST stable disease with a ≥65% tumor volume reduction. T2-signal intensity decreased by ≥50% in 47%, <50% in 41% and increased in 12%. In patients with symptomatic improvement while on therapy and in patients maintaining symptomatic improvement during follow-up, median T2-signal intensity showed a reduction along the time points (3.0, 1.9, 1.2, 1.1; 2.9, 2.0, 1.2, 1.2, respectively); in patients without symptomatic improvement and in those clinically progressing during follow-up, a reduction was not observed. High T2-signal intensity at baseline was observed in patients showing RECIST progression during follow-up.In this series, RECIST detected a lower proportion of responses as compared to volumetric and T2-signal changes. T2-signal reduction seemed to better reflect symptomatic improvement. High T2-signal intensity at baseline was related to a higher proportion of further progression.

Aggressive Fibromatosis

10.1002/cam4.3973

Cite

Citations (6)

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy

British Journal of Cancer (2008)

Francesco Graziano Annamaria Ruzzo Fotios Loupakis Daniele Santini Vincenzo Catalano

We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC). The tandem repeat polymorphism (VNTR) in TS 5′-untranslated region (5′-UTR), which consists of two (2R) or three (3R) 28-bp repeated sequences, with or without a G/C nucleotide change in 3R carriers (3G or 3C) and a 6-bp insertion/deletion (6+/6−) in the TS 3′-UTR, was studied. The distinction between high (2R/3G, 3C/3G and 3G/3G) and low (2R/2R, 2R/3C and 3C/3C) TS expression genotypes according to the 5′-UTR VNTR+G/C nucleotide change showed significant association with tumour response (P=0.01). In particular, high TS expression genotypes were found in 8 out of 34 patients (23.5%) with complete or partial response and in 24 out of 46 patients (52%) with stable disease and disease progression. Liver-only MCRC patients are a homogeneous and clinical relevant subgroup that may represent an ideal setting for studying the actual influence of TS polymorphisms.

10.1038/sj.bjc.6604555

Cite

Citations (31)

P424 MEDIASTINAL ROUND CELL SARCOMA WITH PULMONARY ARTERY STENOSIS: CLINICAL USEFULNESS OF CARDIAC MRI IN CARDIO–ONCOLOGY

European Heart Journal Supplements (2023)

Maria Laura Canale Isabella Bisceglia Giuseppina Gallucci Fabio Maria Turazza Massimiliano Camilli

Abstract Case description: a previously healthy 26–year–old man presented with dyspnea on exertion and dry cough. CT scan revealed a large mediastinal mass with displacement of great vessels and trachea and pericardial effusion. Cardiac MRI showed the huge mediastinal mass, literally leaning on the heart with signs of compression of the pulmonary artery (Figure 1) with the typical D–shape of inter ventricular septum. Pericardial effusion did not compress the RV due to high intraventricular pressure. At baseline echo the mass simulated pulmonary artery stenosis as a consequence of pulmonary artery “ab extrinseco” compression. Surgical biopsy showed Ewing sarcoma lately redefined into undifferentiated round cell sarcoma so the patient started chemotherapy with VAI (vincristine, adriblastine, and ifosfamide) x6 followed by maintenance etoposide and ifosfamide (no anthraciclines for risk of cardiac toxicity). After induction phase MRI showed a partial response to treatment; mediastinal mass further reduced at the end of maintenance (Figure 2). Pericardial effusion disappeared and peak velocity of pulmonary artery went back to normal level at echo. Our patient underwent surgery with en–block removal of mediastinal mass with pericardium and anonymous vein and partial pulmonary upper left lobe resection with R0 resection. Pathology report confirmed an undifferentiated round cell sarcoma (possible embryonal origin, FISH analysis for EWS/FUS genes and 12p negative). Adjuvant mediastinal radiotherapy was delivered. The patient is alive without disease recurrence at one–year follow–up. Conclusions cardiac MR offer great tissue characterization (differential diagnosis between malignant and benign masses) inside/outside the heart. CMR is non–invasive/non radiation and ideal technique for surgery indication and follow–up imaging.

Left pulmonary artery

10.1093/eurheartjsupp/suad111.491

Cite

Citations (0)

Is there a role for intraoperative radiation therapy in resectable extremity soft tissue sarcoma beyond external beam radiation therapy?

Cancer Breaking News (2017)

Antonino De Paoli Claudia Sangalli Giacomo Giulio Baldi

No abstract available

External beam radiation

10.19156/cbn.2017.0033

Cite

Citations (0)